Sellas Life Sciences Group
Clinical trials sponsored by Sellas Life Sciences Group, explained in plain language.
A clinical-stage biotech developing immunotherapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for Hard-to-Treat blood cancers: SLS009 trial launches Results expected Dec 2026 (estimated)
-
New hope for Hard-to-Treat blood cancers: SLS009 trial launches
Disease control Recruiting nowThis study tests a new drug called SLS009, alone or with other medicines, in people with blood cancers like leukemia and lymphoma that have come back or not responded to treatment. It also includes newly diagnosed patients with high-risk leukemia. The goal is to see if the drug i…
Phase 1/2 • Sponsor: Sellas Life Sciences Group • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Last-Resort cancer vaccine made available for AML and MDS patients
Disease control Expanded accessThis program provides galinpepimut-S, a cancer vaccine that aims to train the immune system to fight cancer cells, to individual patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have no other treatment options. It is for people who cannot join a cl…
Sponsor: Sellas Life Sciences Group • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC